Sham procedure
( DrugBank: - / KEGG DRUG: - )
3 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 3 | Spinal muscular atrophy | 4 |
| 90 | Retinitis pigmentosa | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 339 | MECP2 duplication syndrome | 1 |
3. Spinal muscular atrophy
Clinical trials : 297 / Drugs : 143 - (DrugBank : 32) / Drug target genes : 54 - Drug target pathways : 82
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
90. Retinitis pigmentosa
Clinical trials : 186 / Drugs : 191 - (DrugBank : 52) / Drug target genes : 43 - Drug target pathways : 87
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
339. MECP2 duplication syndrome
Clinical trials : 2 / Drugs : 3 - (DrugBank : 0) / Drug target gene : 0 - Drug target pathway : 0
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|